Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

Preetesh Jain, Hagop Kantarjian, Keyur P. Patel, Graciela Nogueras Gonzalez, Rajyalakshmi Luthra, Rashmi Kanagal Shamanna, Koji Sasaki, Elias Jabbour, Carlos Guillermo Romo, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Gautam Borthakur, Zeev Estrov, Farhad Ravandi, Susan O'Brien, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

The most common breakpoint cluster region gene-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) transcripts in chronic myeloid leukemia (CML) are e13a2 (b2a2) and e14a2 (b3a2). The impact of the type of transcript on response and survival after initial treatment with different tyrosine kinase inhibitors is unknown. This study involved 481 patients with chronic phase CML expressing various BCR-ABL transcripts. Two hundred patients expressed e13a2 (42%), 196 (41%) expressed e14a2, and 85 (18%) expressed both transcripts. The proportion of patients with e13a2, e14a2, and both achieving complete cytogenetic response at 3 and 6 months was 59%, 67%, and 63% and 73%, 81%, and 82%, respectively, whereas major molecular response rates were 27%, 49%, and 50% at 3 months, 42%, 67%, and 70% at 6 months, and 55%, 83%, and 76% at 12 months, respectively. Median (international scale) levels of transcripts e13a2, e14a2, and both at 3 months were 0.2004, 0.056, and 0.0612 and at 6 months were 0.091, 0.0109, and 0.0130, respectively. In multivariate analysis, e14a2 and both predicted for optimal responses at 3, 6, and 12 months. The type of transcript also predicted for improved probability of event-free (P 5 .043; e14a2) and transformation-free survival (P 5 .04 for both). Compared to e13a2 transcripts, patients with e14a2 (alone or with coexpressed e13a2) achieved earlier and deeper responses, predicted for optimal European Leukemia Net (ELN) responses (at 3, 6, and 12 months) and predicted for longer event-free and transformation-free survival.

Original languageEnglish (US)
Pages (from-to)1269-1275
Number of pages7
JournalBlood
Volume127
Issue number10
DOIs
StatePublished - Mar 10 2016
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Protein-Tyrosine Kinases
Genes
Survival
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multigene Family
Oncogenes
Cytogenetics
Multivariate Analysis

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. / Jain, Preetesh; Kantarjian, Hagop; Patel, Keyur P.; Gonzalez, Graciela Nogueras; Luthra, Rajyalakshmi; Shamanna, Rashmi Kanagal; Sasaki, Koji; Jabbour, Elias; Romo, Carlos Guillermo; Kadia, Tapan M.; Pemmaraju, Naveen; Daver, Naval; Borthakur, Gautam; Estrov, Zeev; Ravandi, Farhad; O'Brien, Susan; Cortes, Jorge.

In: Blood, Vol. 127, No. 10, 10.03.2016, p. 1269-1275.

Research output: Contribution to journalArticle

Jain, P, Kantarjian, H, Patel, KP, Gonzalez, GN, Luthra, R, Shamanna, RK, Sasaki, K, Jabbour, E, Romo, CG, Kadia, TM, Pemmaraju, N, Daver, N, Borthakur, G, Estrov, Z, Ravandi, F, O'Brien, S & Cortes, J 2016, 'Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors', Blood, vol. 127, no. 10, pp. 1269-1275. https://doi.org/10.1182/blood-2015-10-674242
Jain, Preetesh ; Kantarjian, Hagop ; Patel, Keyur P. ; Gonzalez, Graciela Nogueras ; Luthra, Rajyalakshmi ; Shamanna, Rashmi Kanagal ; Sasaki, Koji ; Jabbour, Elias ; Romo, Carlos Guillermo ; Kadia, Tapan M. ; Pemmaraju, Naveen ; Daver, Naval ; Borthakur, Gautam ; Estrov, Zeev ; Ravandi, Farhad ; O'Brien, Susan ; Cortes, Jorge. / Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. In: Blood. 2016 ; Vol. 127, No. 10. pp. 1269-1275.
@article{208b10db8f52455b8eb2dafa64d17798,
title = "Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors",
abstract = "The most common breakpoint cluster region gene-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) transcripts in chronic myeloid leukemia (CML) are e13a2 (b2a2) and e14a2 (b3a2). The impact of the type of transcript on response and survival after initial treatment with different tyrosine kinase inhibitors is unknown. This study involved 481 patients with chronic phase CML expressing various BCR-ABL transcripts. Two hundred patients expressed e13a2 (42{\%}), 196 (41{\%}) expressed e14a2, and 85 (18{\%}) expressed both transcripts. The proportion of patients with e13a2, e14a2, and both achieving complete cytogenetic response at 3 and 6 months was 59{\%}, 67{\%}, and 63{\%} and 73{\%}, 81{\%}, and 82{\%}, respectively, whereas major molecular response rates were 27{\%}, 49{\%}, and 50{\%} at 3 months, 42{\%}, 67{\%}, and 70{\%} at 6 months, and 55{\%}, 83{\%}, and 76{\%} at 12 months, respectively. Median (international scale) levels of transcripts e13a2, e14a2, and both at 3 months were 0.2004, 0.056, and 0.0612 and at 6 months were 0.091, 0.0109, and 0.0130, respectively. In multivariate analysis, e14a2 and both predicted for optimal responses at 3, 6, and 12 months. The type of transcript also predicted for improved probability of event-free (P 5 .043; e14a2) and transformation-free survival (P 5 .04 for both). Compared to e13a2 transcripts, patients with e14a2 (alone or with coexpressed e13a2) achieved earlier and deeper responses, predicted for optimal European Leukemia Net (ELN) responses (at 3, 6, and 12 months) and predicted for longer event-free and transformation-free survival.",
author = "Preetesh Jain and Hagop Kantarjian and Patel, {Keyur P.} and Gonzalez, {Graciela Nogueras} and Rajyalakshmi Luthra and Shamanna, {Rashmi Kanagal} and Koji Sasaki and Elias Jabbour and Romo, {Carlos Guillermo} and Kadia, {Tapan M.} and Naveen Pemmaraju and Naval Daver and Gautam Borthakur and Zeev Estrov and Farhad Ravandi and Susan O'Brien and Jorge Cortes",
year = "2016",
month = "3",
day = "10",
doi = "10.1182/blood-2015-10-674242",
language = "English (US)",
volume = "127",
pages = "1269--1275",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

AU - Jain, Preetesh

AU - Kantarjian, Hagop

AU - Patel, Keyur P.

AU - Gonzalez, Graciela Nogueras

AU - Luthra, Rajyalakshmi

AU - Shamanna, Rashmi Kanagal

AU - Sasaki, Koji

AU - Jabbour, Elias

AU - Romo, Carlos Guillermo

AU - Kadia, Tapan M.

AU - Pemmaraju, Naveen

AU - Daver, Naval

AU - Borthakur, Gautam

AU - Estrov, Zeev

AU - Ravandi, Farhad

AU - O'Brien, Susan

AU - Cortes, Jorge

PY - 2016/3/10

Y1 - 2016/3/10

N2 - The most common breakpoint cluster region gene-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) transcripts in chronic myeloid leukemia (CML) are e13a2 (b2a2) and e14a2 (b3a2). The impact of the type of transcript on response and survival after initial treatment with different tyrosine kinase inhibitors is unknown. This study involved 481 patients with chronic phase CML expressing various BCR-ABL transcripts. Two hundred patients expressed e13a2 (42%), 196 (41%) expressed e14a2, and 85 (18%) expressed both transcripts. The proportion of patients with e13a2, e14a2, and both achieving complete cytogenetic response at 3 and 6 months was 59%, 67%, and 63% and 73%, 81%, and 82%, respectively, whereas major molecular response rates were 27%, 49%, and 50% at 3 months, 42%, 67%, and 70% at 6 months, and 55%, 83%, and 76% at 12 months, respectively. Median (international scale) levels of transcripts e13a2, e14a2, and both at 3 months were 0.2004, 0.056, and 0.0612 and at 6 months were 0.091, 0.0109, and 0.0130, respectively. In multivariate analysis, e14a2 and both predicted for optimal responses at 3, 6, and 12 months. The type of transcript also predicted for improved probability of event-free (P 5 .043; e14a2) and transformation-free survival (P 5 .04 for both). Compared to e13a2 transcripts, patients with e14a2 (alone or with coexpressed e13a2) achieved earlier and deeper responses, predicted for optimal European Leukemia Net (ELN) responses (at 3, 6, and 12 months) and predicted for longer event-free and transformation-free survival.

AB - The most common breakpoint cluster region gene-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) transcripts in chronic myeloid leukemia (CML) are e13a2 (b2a2) and e14a2 (b3a2). The impact of the type of transcript on response and survival after initial treatment with different tyrosine kinase inhibitors is unknown. This study involved 481 patients with chronic phase CML expressing various BCR-ABL transcripts. Two hundred patients expressed e13a2 (42%), 196 (41%) expressed e14a2, and 85 (18%) expressed both transcripts. The proportion of patients with e13a2, e14a2, and both achieving complete cytogenetic response at 3 and 6 months was 59%, 67%, and 63% and 73%, 81%, and 82%, respectively, whereas major molecular response rates were 27%, 49%, and 50% at 3 months, 42%, 67%, and 70% at 6 months, and 55%, 83%, and 76% at 12 months, respectively. Median (international scale) levels of transcripts e13a2, e14a2, and both at 3 months were 0.2004, 0.056, and 0.0612 and at 6 months were 0.091, 0.0109, and 0.0130, respectively. In multivariate analysis, e14a2 and both predicted for optimal responses at 3, 6, and 12 months. The type of transcript also predicted for improved probability of event-free (P 5 .043; e14a2) and transformation-free survival (P 5 .04 for both). Compared to e13a2 transcripts, patients with e14a2 (alone or with coexpressed e13a2) achieved earlier and deeper responses, predicted for optimal European Leukemia Net (ELN) responses (at 3, 6, and 12 months) and predicted for longer event-free and transformation-free survival.

UR - http://www.scopus.com/inward/record.url?scp=84960864211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960864211&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-10-674242

DO - 10.1182/blood-2015-10-674242

M3 - Article

C2 - 26729897

AN - SCOPUS:84960864211

VL - 127

SP - 1269

EP - 1275

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -